Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 20Docetaxel 8Carboplatin 8Fluorouracil 6Cisplatin 6Nivolumab 5fludarabine 4Trastuzumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Cyclophosphamide 4Biopsy 4Bevacizumab 4fludarabine phosphate 3durvalumab 3atezolizumab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Capecitabine 3Albumin-Bound Paclitaxel 3ulixertinib 2tisotumab vedotin 2spartalizumab 2belinostat 2adavosertib 2X-Rays 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × enfortumab vedotin × Head & Neck × Clear all
NCT04225117 2026-04-13

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Astellas Pharma Inc

Phase 2 Active not recruiting
329 enrolled 23 charts
BreastGastrointestinalHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡